Cargando…
A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (...
Autores principales: | Zeng, Zhirui, Hu, Chujiao, Ruan, Wanyuan, Zhang, Jinjuan, Lei, Shan, Yang, Yushi, Peng, Pailan, Pan, Feng, Chen, Tengxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500319/ https://www.ncbi.nlm.nih.gov/pubmed/36159801 http://dx.doi.org/10.3389/fimmu.2022.1001381 |
Ejemplares similares
-
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
por: Cao, Wenpeng, et al.
Publicado: (2023) -
A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy
por: Pan, Runsang, et al.
Publicado: (2022) -
Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
por: Hu, Chujiao, et al.
Publicado: (2022) -
A 2-Gene Signature Related to Interferon-Gamma Predicts Prognosis and Responsiveness to Immune Checkpoint Blockade of Glioma
por: Li, Yongzhe, et al.
Publicado: (2022) -
Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)